Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.China Medicine has received a patent from the Australia Patent Office for recombinant aflatoxin detoxifizyme. The patent is valid through January 13, 2025.
Subscribe to our email newsletter
Recombinant aflatoxin detoxifizyme (rADTZ) is said to be an innovative product that has the potential to detoxify aflatoxin (AFT), a potential cancer causing agent, in food and feed. It is a compound that is a derivation of aflatoxin-detoxifizyme (ADTZ), an extracellular enzyme.
Developed by Guangzhou Co-Win Bioengineering, a subsidiary of China Medicine, rADTZ can be used as an additive to remove aflatoxins from animal feed as well as other food products. The company intends to develop rADTZ for this and other applications.
The company is currently testing rADTZ on animal feed and is scheduled to begin working with the Chinese Department of Agriculture on a large scale experiment in order to meet national standards and apply for production permits. Once the company receives production permits, it expects to begin trial sales of rADTZ by the end of 2008.
Senshan Yang, chairman and CEO of China Medicine, said: “We are proud to announce that we have achieved a major milestone in being granted a patent for rADTZ in Australia. This is a major breakthrough for China Medicine and it opens up the opportunity to expand our business overseas.”